BCIQ Profiles

Company Profile Report

Syros discontinues single agent tamibarotene

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The data were presented at the American Society

Read the full 461 word article

How to gain access

Continue reading with a
two-week free trial.